Search - tctmd.com

Displaying 181 - 200 of 223

Sort: Relevancy | Date

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

News Daily News

En los Ensayos Intervencionistas el Tratamiento Médico Óptimo podría acarrear Formación y Técnicas Nuevas

Todd Neale

December 20, 2015

News Daily News

¿Estatinas para el Manejo de la Calcificación Aórtica? Un Estudio de Imágenes Debate sobre el Papel de las LBD en la Enfermedad de la Válvula Aórtica

Shelley Wood

December 16, 2015

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

Las Noticias Negativas sobre las Estatinas se asociaron a su Interrupción y a Más Riesgo CV

Michael O'Riordan

December 02, 2015

News Daily News

El Riesgo de ACV de las Oclusiones Carotídeas parece Muy Bajo en Pacientes Asintomáticos Contemporáneos

September 29, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

News Industry News

FDA approves Repatha to treat certain patients with high cholesterol

August 28, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

August 13, 2015

News Daily News

La Evidencia de la Regresión de la Placa Avala el Uso Combinado de Ezetimibe+Estatinas

L.A. McKeown

July 29, 2015

News Industry News

Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension

July 28, 2015

News Industry News

Lilly Provides Update on Evacetrapib Phase 3 Trial

July 27, 2015

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet

July 23, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

Advertisement

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

En los Ensayos Intervencionistas el Tratamiento Médico Óptimo podría acarrear Formación y Técnicas Nuevas

¿Estatinas para el Manejo de la Calcificación Aórtica? Un Estudio de Imágenes Debate sobre el Papel de las LBD en la Enfermedad de la Válvula Aórtica

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Las Noticias Negativas sobre las Estatinas se asociaron a su Interrupción y a Más Riesgo CV

El Riesgo de ACV de las Oclusiones Carotídeas parece Muy Bajo en Pacientes Asintomáticos Contemporáneos

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

FDA approves Repatha to treat certain patients with high cholesterol

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

La Evidencia de la Regresión de la Placa Avala el Uso Combinado de Ezetimibe+Estatinas

Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension

Lilly Provides Update on Evacetrapib Phase 3 Trial

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content